Grant of Options
Faron Pharmaceuticals has granted 2,173,000 options over ordinary shares under its Share Option Plan 2026, representing 0.95% of the fully diluted share capital. These options are exercisable after June 1, 2029, with an exercise price of €0.50 per share for most recipients and €0.53 for US nationals. A total of 660,000 options were granted to directors and 818,000 to other persons discharging managerial responsibilities, with the remaining 695,000 allocated to other company personnel.
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Company announcement | July 01, 2026 at 13:00:00 EEST |
TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company’s board has confirmed the grant of a total of 2,173,000 options over ordinary shares in the Company (“Options”) under the Company’s Share Option Plan 2026.
The Options have been allocated under the Share Option Plan 2026 and are exercisable after 1 June 2029, vesting 100%. The exercise price for Options allocated under the Share Option Plan is € 0.50 per share based on the resolution of the Annual General Meeting on 4 May 2026 and € 0.53 for the recipients of options who are US nationals. The terms of the Share Option Plan 2026 are available on the Company’s website.
The granted 2,173,000 Options entitle the option holders to subscribe for a total of 2,173,000 new ordinary shares in the Company, if exercised in full, and represent 0.95 % of the fully diluted ordinary share capital of the Company on the grant date.
Included in the number of Options granted are the following Options which were issued to directors and other persons discharging managerial responsibilities (“PDMRs”):
| Director | Options grante d |
|---|---|
| Colin Bond | 60,000 |
| Christine Roth | 60,000 |
| George Golumbeski | 60,000 |
| Juho Jalkanen | 220,000 |
| Marie-Louise Fjällskog | 60,000 |
| Tuomo Pätsi | 200,000 |
| Total directors | 660,000 |
| Other PDMR | |
| Maija Hollmén | 38,000 |
| Vesa Karvonen | 120,000 |
| Jurriaan Dekkers | 170,000 |
| Petri Bono | 170,000 |
| Ralph Hughes | 120,000 |
| Kaisa Kyttä | 100,000 |
| Joab Wiliamson | 100,000 |
| Total other PDMRs | 818,000 |
| Total Company personnel | 695,000 |
About Bexmarilimab
About Faron Pharmaceuticals Ltd.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | a. Colin Bond b. Christine Roth c. George Golumbeski d. Juho Jalkanen e. Marie-Louise Fjällskog f. Tuomo Pätsi g. Maija Hollmén h. Vesa Karvonen i. Jurriaan Dekkers j. Petri Bono k. Ralph Hughes l. Kaisa Kyttä m. Joab Williamson |
| 2 | Reason for notification | |
| a. | Position/Status | Person discharging managerial responsibilities/person closely associated |
| b. | Initial notification/ Amendment | Initial notification |
| a. | Name | Faron Pharmaceuticals Oy |
| b. | LEI | 7437009H31TO1DC0EB42 |
| a. | Description of the financial instrument, type of instrument Identification Code | Options over new ordinary shares ISIN: FI4000153309 |
| b. | Nature of the transaction | Grant of options made under the Faron Share Option Plan 2026. The exercise price for Options allocated under the Share Option Plan is € 0.50 per share and € 0.53 for the recipients of options who are US nationals. |
| c. | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| a. € 0.50 b. € 0.53 c. € 0.53 d. € 0.50 e. € 0.53 f. € 0.50 g. € 0.50 h. € 0.50 i. € 0.50 j. € 0.50 k. € 0.50 l. € 0.50 m. € 0.50 | 60,000 60,000 60,000 300,000 60,000 200,000 38,000 120,000 170,000 170,000 120,000 100,000 100,000 | |
| d. | Aggregated information - Aggregated Volume - Price | Nil |
| f. | Place of the transaction | Turku |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.